Experts Discuss the Potential Role of GLP-1 Receptor Agonists in Breast Cancer Outcomes and Survivorship Care

In this interview with Pharmacy Times, Bernard Fuemmeler, PhD, MPH, Professor and Gordon D. Ginder, MD Chair in Cancer Research, and Kristina Tatum, PsyD, MS, Instructor at VCU School of Public Health, discuss their emerging research evaluating the association between GLP-1 receptor agonist use and improved survival outcomes among patients with breast cancer. The experts explain that the findings may be linked to improvements in obesity-related, metabolic, and cardiovascular comorbidities that can influence tumor biology, though further research is needed to better understand the underlying mechanisms. They also discuss the importance of identifying which patients may benefit most from GLP-1 therapies and the need for additional clinical guidance as agents such as semaglutide and tirzepatide become more widely used. Read the full article on their study here.